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The original article \[[@CR1]\] contains an error whereby Fig. 7 displays incorrect results; the correct version of Fig. 7 can be viewed ahead in this Correction article and should be considered in place of the original article's version of Fig. [7](#Fig7){ref-type="fig"}.Fig. 7Target relationship between miR-325-3p and RIPK3. **a** The binding sites between the 3′UTR of RIPK3 and miR-325-3p predicted by TargetScanHuman 7.2. **b** A dual-luciferase reporter assay validated the target relationship between miR-325-3p and the 3′UTR of RIPK3. \*\**P *\< 0.01 between the wild-type and mutated 3′UTR of RIPK3. **c**, **d** The differential expression of RIPK3 mRNA (**c**) or protein (**d**) in the sham-operated mice and the MI mice. \*\**P *\< 0.01 compared to the mice that received the sham operation. **e**, **f** The influence of miR-325-3p dysregulation on the expression of RIPK3 mRNA (**e**) and protein (**f**) in MI mice. \*\**P *\< 0.01 compared to MI mice treated with agomiR-control. MI, myocardial infarction; agomiR-325-3p, miR-325-3p agomir; antagomiR-325-3p, miR-325-3p antagomir; agomiR-control, scrambled agomir or antagomir control; RIPK3, receptor-interacting serine/threonine protein kinase 3
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